2026 Agenda

Exploring how clinic owners and network leaders are expanding capacity through care-team redesign and smarter technology adoption in the face of physician and embryologist shortages.

Attendees will discuss and gain insight into:

• Where advanced practice provider scope is working, and where operators disagree on the trade-offs
• How to roll a new care model across multiple sites without losing consistency
• What's genuinely deployment-ready versus still development-stage across embryology AI, automation and robotics
• Best practice considerations for technology buying decision

Format: Closed-door roundtable, 25–35 senior clinic and network leaders, private room.

Gain a full, straight-talking picture of where fertility policy is moving at both federal and state level and the opportunities presented by changes.

Uncover exactly what new rules mean for how patients find their way to your clinic and get clear on:

• How the new federal employer benefit rule could shift acquisition toward employer relationships over state geography
• What "covered" really means state by state, and where the mandate is weaker than it looks on paper
• What the November 2026 midterms could change about the current coalition backing IVF-friendly federal policy

Format: Closed-door roundtable, 25–35 senior clinic and network leaders, private room.

Where are the most promising areas of scientific progress? How is thinking evolving around clinical trials, evidence and inclusion? What will define the next generation of therapies?

Hear from a leading pharmaceutical voice on where the industry is placing its bets. From menopause and reproductive health to cardiometabolic disease and adjacent conditions understand what expanded pharma ambitions mean for women’s health.

Focus on fertility care is increasing, not just within our industry but also culturally, economically, and politically.

The implications for women's healthcare and lives globally are significant. As declining birth rates reshape policy conversations, with countries including China, South Korea, and Japan responding through targeted initiatives, to address falling fertility rates and fertility preservation and reproductive planning moving increasingly into mainstream conversation. This session explores what's driving the gap between demand and access, the role of AI and digital health in diagnostics and treatment, and how women are engaging with fertility treatments in the age of consumerisation of health.

Speakers will examine innovation across drug development, diagnostics, and medical devices, and how employers, policymakers, and healthcare organizations can better support fertility care access. EMD Serono will share how the company is working to expand affordability through pricing initiatives — including Most Favored Nation pricing — and partnerships with the U.S. government, alongside broader efforts to advance access to fertility treatment worldwide.

Attendees will leave with a clearer view of how demographic trends, innovation, and policy are converging to shape fertility care for women globally.

This invite-only session to provide an update on the reproductive healthcare landscape in a fragmented U.S. operating environment.

There will be brief remarks then conversation focused on industry-specific ways to prepare and respond as companies as well as executives. Experts from Don’t Ban Equality, Rhia Ventures and Center for Reproductive Rights to provide remarks.